Delayed sodium thiosulphate administration reduces Cisplatin efficacy on mouse EMT6 tumour cells in Vitro

Journal of Otolaryngology - Head and Neck Surgery

Volumn 37, Issue 5, 2008, Pages 638-641

  Yee, May Sann ^a,d   Blakley, Brian W ^b   Begleiter, Asher ^c   Leith, Marsha ^c  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF MANITOBA   (Canada)

^c UNIVERSITY OF MANITOBA   (Canada)

^d HEALTH SCIENCES CENTRE   (Canada)

Author keywords

Cancer; Chemotherapy; Cisplatin; Hair cell; Hearing; Ototoxicity; Sodium thiosulphate

Indexed keywords

CISPLATIN; SODIUM THIOSULFATE;

ANIMAL CELL; ARTICLE; CELL GROWTH; CLONOGENIC ASSAY; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; IN VITRO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR CELL;

ANALYSIS OF VARIANCE; ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; CELLS, CULTURED; CISPLATIN; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; DRUG TOXICITY; HALF-LIFE; MICE; MICE, INBRED STRAINS; PROBABILITY; SENSITIVITY AND SPECIFICITY; THIOSULFATES; TIME FACTORS;

EID: 64349117839     PISSN: 19160216     EISSN: None     Source Type: Journal    
DOI: 10.2310/7070.2008.0082     Document Type: Article

References (20)

1. Church MW, Kaltenbach JA, Blakley BW, Burgio DL. The comparative effects of sodium thiosulfate, diethyldithiocarbamate, fosfomycin and WR-2721 on ameliorating cisplatin-induced ototoxicity. Hear Res 1995;86:195-203.
2. Kaltenbach JA, Church MW, Blakley BW, et al. Comparison of five agents in protecting the cochlea against the ototoxic effects of cisplatin in the hamster. Otolaryngol Head Neck Surg 1997;117: 493-500.
3. Abe R, Akiyoshi T, Baba T. 'Two-route chemotherapy' using cisplatin and its neutralizing agent, sodium thiosulfate, for intraperitoneal cancer. Oncology 1990;47:422-6.
4. Elferink F, van der Vijgh WJ, Klein I, Pinedo HM. Interaction of cisplatin and carboplatin with sodium thiosulfate: reaction rates and protein binding. Clin Chem 1986;32:641-5.
5. Nagai N, Hotta K, Yamamura H, Ogata H. Effects of sodium thiosulfate on the pharmacokinetics of unchanged cisplatin and on the distribution of platinum species in rat kidney: protective mechanism against cisplatin nephrotoxicity. Cancer Chemother Pharmacol 1995;36:404-10.
6. Muldoon LL, Pagel MA, Kroll RA, et al. Delayed administration of sodium thiosulfate in animal models reduces platinum ototoxicity without reduction of antitumor activity. Clin Cancer Res 2000;6:309-15.
7. Doolittle ND, Muldoon LL, Brummett RE, et al. Delayed sodium thiosulfate as an otoprotectant against carboplatin-induced hearing loss in patients with malignant brain tumors. Clin Cancer Res 2001;7:493-500.
8. Moroso MJ, Blair RL. A review of cis-platinum ototoxicity. J Otolaryngol 1983;12:365-9.
9. Blakley BW, Myers SF. Patterns of hearing loss resulting from cisplatinum therapy. Otolaryngol Head Neck Surg 1993;109(3 Pt 1):385-91.
10. Oriana S, Bohm S, Spatti G, et al. A preliminary clinical experience with reduced glutathione as protector against cisplatin-toxicity. Tumori 1987;73:337-40.
11. Rosenblum ML, Knebel KD, Wheeler KT, et al. Development of an in vitro colony formation assay for the evaluation of in vivo chemotherapy of a rat brain tumor. In Vitro 1975;11:264-73.
12. Brown DB, Khokhar AR, Hacker MP, et al. Synthesis and antitumor activity of new platinum complexes. J Med Chem 1982;25:952-6.
13. Wozniak K, Walter Z. Induction of DNA-protein cross-links by platinum compounds. Z Naturforsch [C] 2000;55:731-6.
14. Doolittle ND, Miner ME, Hall WA, et al. Safety and efficacy of a multicenter study using intraarterial chemotherapy in conjunction with osmotic opening of the blood-brain barrier for the treatment of patients with malignant brain tumors. Cancer 2000;88:637-47.
15. Dedon PC, Borch RF. Characterization of the reactions of platinum antitumor agents with biologic and nonbiologic sulfur-containing nucleophiles. Biochem Pharmacol 1987;36:1955-64.
16. Neuwelt EA, Brummett RE, Remsen LG, et al. In vitro and animal studies of sodium thiosulfate as a potential chemoprotectant against carboplatin-induced ototoxicity. Cancer Res 1996;56:706-9.
17. Andrews P, Wung W, Howell S. A high-performance liquid chromatographic assay with improved selectivity for cisplatin and active platinum (II) complexes in plasma ultrafiltrate. Analyt Biochem 1984;143:46-56.
18. Abe R, Akiyoshi T, Baba T. Inactivation of cis-diamminedichlor-oplatinum (II) in blood by sodium thiosulfate. Oncology 1990;47: 65-9.
19. Kumar P, Robbins KT. Treatment of advanced head and neck cancer with intra-arterial cisplatin. Curr Oncol Rep 2001;3:59-65.
20. Blakley BW, Cohen JI, Doolittle ND, et al. Strategies for prevention of toxicity caused by platinum-based chemotherapy: review and summary of the annual meeting of the Blood-Brain Barrier Disruption Program, Gleneden Beach, Oregon, March 10, 2001. Laryngoscope 2002;112:1997-2001.